中国经济网北京5月8日讯威腾电气(688226.SH)昨日晚间发布股东询价转让计划书。拟参与威腾电气首 发前股东询价转让(以下简称"本次询价转让")的股东为江苏威腾投资管理有限公司、镇江博爱投资有限 公司。本次询价转让股份的数量为3,253,698股，占总股本的比例为1.73%，转让原因均为自身资金需 求。 威腾电气首次公开发行募集资金总额为2.50亿元，扣除发行费用后，募集资金净额为2.06亿元。威腾电 气最终募集资金净额比原计划少2.00亿元。威腾电气于2021年6月30日披露的招股书显示，公司拟募集 资金4.06亿元，其中，1.63亿元用于母线车间智能化升级改造项目，1.42亿元用于年产2000套智能化中 压成套开关设备及63000台智能型(可通信)低压电器项目，5031.00万元用于研发中心建设项目，5000.00 万元用于补充流动资金。 威腾电气公开发行新股的发行费用合计4450.76万元(不含增值税金额)，其中保荐机构中信证券股份有限 公司获得承销保荐费3000.00万元。 2025年1月7日，威腾电气发布的向特定对象发行A股股票上市公告书显示，本次发行数量30,000,000 股，发行价格19. ...

以下文章来源于解码LP ，作者吴琼 解码LP . 投资界（PEdaily.cn）旗下，专注募资动态 欢迎加入投资界读者群 募资不易。 作者 I 吴琼 报道 I 投资界-解码LP 募资最新一幕。 投资界—解码LP获悉，国家中小企业发展基金有限公司完成第七批第一支子基金签约工 作，即深创投中小企业发展基金（苏州）合伙企业（有限合伙），总规模20亿元。这一 次，深创投为新基金管理人。 放眼创投圈，国家中小企业发展基金向来出手活跃。此次签约拉开第七批子基金序幕， 意味着有望迎来一波密集出资。对于一众苦于募资的GP而言，一场新比拼开始了。 国家级母基金，投了深创投 从过往出资来看，国家中小企业发展基金对GP的遴选颇为严格。印象深刻的是，去年6 月母基金一口气出资6家GP，包括普华资本、基石资本、达晨财智、元璟资本、通和毓 承、国中资本等知名机构。其实这次也并非国家中小企业发展基金首次联手深创投，此 前深创投中小企业发展基金（新疆）有限合伙企业已在新疆乌鲁木齐成立。 时间回到去年7月，国家中小企业发展基金发布第七批子基金管理机构遴选公告，子基金 将通过市场化手段扩大对中小企业的股权投资规模，支持投早投小投创新，重点支持种 ...

Core Points - Gannee Pharmaceutical recently disclosed a significant change in shareholder equity, with Beijing Xute Hongda Technology Co., Ltd. reducing its stake in the company [1][2] - The equity change period was from April 22, 2025, to April 24, 2025, during which Xute Hongda reduced its holdings by 849,822 shares, representing 0.14% of Gannee's total share capital [1][2] - After the change, Xute Hongda holds 40,634,035 shares, accounting for 6.76% of Gannee's total share capital, while its concerted actor, Gan Zhongru, holds 205,643,757 shares, representing 34.21% [1][2] Company Information - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, while Xute Hongda is the second largest shareholder [2] - Gan Zhongru has been the controlling shareholder and actual controller of Gannee since 2020, serving as the chairman of the company [2] - Gannee Pharmaceutical was listed on the Shanghai Stock Exchange on June 29, 2020, with an initial public offering (IPO) of 40.2 million shares at a price of 63.32 yuan per share [2][3] Fundraising Activities - Gannee Pharmaceutical raised a total of 2.545 billion yuan through its IPO, with a net amount of 2.441 billion yuan after expenses [2][3] - The funds raised were intended for various projects, including marketing network construction and the registration of insulin products in the U.S. [2] - In 2023, Gannee issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [3]

Group 1 - The fundraising process involves various combinations of projects and limited partners (LPs) to attract investments [2][3][6] - Investment teams quickly rearrange existing projects to align with the fundraising team's needs, often presenting a different set of projects during fundraising compared to actual investments made later [6][15] - The fundraising team actively seeks out LPs across the country, regardless of the suitability of the LPs, to expand their resource pool [11][12] Group 2 - The key to successful fundraising is having a thick skin and being adaptable to the needs of potential LPs [10][11] - The investment logic is primarily driven by the need to secure fundraising, leading to fragmented investment strategies that may not align with industry resources [15][16] - Institutions are under pressure to provide guarantees on annual returns to LPs due to poor past performance, leading to a focus on projects with acceptable return rates [18]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the year 2024, indicating potential challenges in its operational performance and market conditions [1][2][3]. Financial Performance - The company achieved operating revenue of 2.005 billion yuan in 2024, a decrease of 39.24% compared to 3.299 billion yuan in 2023 [2][3]. - The net profit attributable to shareholders was 41.11 million yuan, down 92.03% from 515.64 million yuan in the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was -28.13 million yuan, compared to 447.66 million yuan in 2023, reflecting a decline of 106.2% [3]. - The net cash flow from operating activities was 704.67 million yuan, a decrease of 34.26% from 1.072 billion yuan in 2023 [3]. Capital Raising and Stock Issuance - The company was listed on the Sci-Tech Innovation Board on December 30, 2020, raising a total of 2.168 billion yuan through the issuance of 38.71 million shares at a price of 56.00 yuan per share [4]. - The total amount raised from the two fundraising rounds was 7.17 billion yuan [5]. - The company plans to distribute dividends to shareholders, proposing a capital reserve transfer of 4 shares for every 10 shares held and a cash dividend of 10.40 yuan for every 10 shares [5].

Core Insights - The company, Capital Online, reported a revenue of 1.397 billion yuan for the year 2024, representing a year-on-year growth of 12.35% [1][2] - The net profit attributable to shareholders was -303 million yuan, an improvement from -340 million yuan in the previous year, indicating a 10.86% reduction in losses [1][2] - The net cash flow from operating activities reached 241 million yuan, showing a significant increase of 42.51% compared to the previous year [1][2] Financial Performance - Revenue for 2024 was 1,396,789,414.24 yuan, up from 1,243,287,334.15 yuan in 2023 [2] - The net profit attributable to shareholders for 2024 was -303,144,022.54 yuan, compared to -340,078,976.82 yuan in 2023, marking a 10.86% improvement [2] - The net profit after excluding non-recurring gains and losses was -295,912,126.32 yuan for 2024, an improvement from -330,992,782.11 yuan in 2023, reflecting a 10.60% reduction in losses [2] - The net cash flow from operating activities was 240,905,307.74 yuan, up from 169,048,663.77 yuan in 2023, indicating a 42.51% increase [2] Shareholder Metrics - Basic and diluted earnings per share for 2024 were both -0.6126 yuan, an improvement of 15.91% from -0.7285 yuan in 2023 [2] - The weighted average return on equity was -29.90% for 2024, an improvement from -32.75% in 2023 [2] Asset and Equity Position - Total assets at the end of 2024 were 1.955 billion yuan, down 6.24% from 2.085 billion yuan at the end of 2023 [2] - The net assets attributable to shareholders increased to 931 million yuan, up 7.23% from 868 million yuan at the end of 2023 [2] Historical Performance - The company has reported losses for three consecutive years, with net profits attributable to shareholders of -189 million yuan in 2022, -340 million yuan in 2023, and -303 million yuan in 2024 [1][2]

12 月了，各投资人陆续开始年终总结。我也凑个热闹。 回看我的 2024 ，在 lp 爸爸的大力鞭策下，在证监会交易所的严格要求下，我精进迭代了以下六方面的 能力：对赌回购，返投落地，退出，募资， FA ，副业。 每项技能可能还可以再叠加 buff ，输出 plus 技能。 然后，我先默认点进本文的朋友，都已经能比较好理解 lp ，返投， fa 的概念。 技能 1 对赌回购 技能 1+ 无限连带责任 技能 1++ 差异化定价并购退出 作为国资基金，没有对赌回购肯定是不行的。甚至，需要创始人无限连带，只有公司回购都是不足以让 lp 爸爸满意的。 但是，创始人不同意怎么办？ 今年以来，很多上市公司对初创公司的并购，都采用了叫做"差异化定价"的策略。并购的时候，给投资 人高估值，给团队低估值，大家都有了体面。 甚至，再加个拖售权。拖售权 + 差异化定价，即使没有回购，大概率也是能说服投委的。 要么回购，要么拖售权 + 差异化定价，创始人你选一个吧。 "宋总你这谈判策略太强了" 我说：都是合伙人管理有方。 技能 2 返投落地 说的太好了。感谢lp爸爸给我提升的机会。 技能 3 退出 技能 3+ 带年化利率退出 技能 ...